Humana Inc. (NYSE:HUM) had its target price hoisted by BMO Capital Markets from $290.00 to $300.00 in a research note published on Friday. They currently have an outperform rating on the insurance provider’s stock.
HUM has been the topic of several other research reports. ValuEngine downgraded shares of Humana from a buy rating to a hold rating in a report on Tuesday, October 10th. BidaskClub raised shares of Humana from a sell rating to a hold rating in a report on Wednesday, August 23rd. Jefferies Group LLC reaffirmed a hold rating and issued a $257.00 price target on shares of Humana in a report on Friday, October 13th. J P Morgan Chase & Co downgraded shares of Humana from an overweight rating to a neutral rating and set a $253.00 price target on the stock. in a report on Monday, October 9th. Finally, Royal Bank Of Canada reaffirmed a hold rating and issued a $245.00 price target on shares of Humana in a report on Tuesday, October 10th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $252.81.
Humana (HUM) traded down $3.45 during mid-day trading on Friday, reaching $240.94. 1,445,100 shares of the company were exchanged, compared to its average volume of 1,376,997. The stock has a market capitalization of $34,913.58, a P/E ratio of 20.85, a P/E/G ratio of 1.68 and a beta of 0.91. Humana has a 52-week low of $186.25 and a 52-week high of $264.56. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm’s revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.18 earnings per share. analysts predict that Humana will post 11.64 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/bmo-capital-markets-increases-humana-inc-hum-price-target-to-300-00/1775808.html.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.66%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is 12.59%.
In other Humana news, VP Timothy S. Huval sold 7,803 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the completion of the sale, the vice president now directly owns 8,831 shares in the company, valued at $2,279,634.34. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total transaction of $770,759.58. Following the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The disclosure for this sale can be found here. Insiders have sold 20,660 shares of company stock valued at $5,319,600 in the last ninety days. 0.80% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Independent Portfolio Consultants Inc. grew its stake in Humana by 22.1% during the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares during the period. Creative Planning grew its stake in Humana by 0.3% during the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the period. State of Alaska Department of Revenue grew its stake in Humana by 467.2% during the second quarter. State of Alaska Department of Revenue now owns 9,422 shares of the insurance provider’s stock worth $2,266,000 after buying an additional 7,761 shares during the period. Mn Services Vermogensbeheer B.V. grew its stake in Humana by 509.6% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 24,236 shares of the insurance provider’s stock worth $5,832,000 after buying an additional 20,260 shares during the period. Finally, Eqis Capital Management Inc. grew its stake in Humana by 2.7% during the second quarter. Eqis Capital Management Inc. now owns 9,452 shares of the insurance provider’s stock worth $2,274,000 after buying an additional 247 shares during the period. Institutional investors own 96.15% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with our FREE daily email newsletter.